Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

Therapeutic Doses of Efzofitimod Significantly Improve Multiple Pulmonary Sarcoidosis Efficacy Measures

Sunday, September 10, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Atyr Pharma has reported that therapeutic doses of efzofitimod significantly improve multiple efficacy measures in patients with pulmonary sarcoidosis. The results from clinical trials indicate a promising therapeutic profile for efzofitimod. This development highlights the potential of the drug in addressing this challenging condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • Efzofitimod shows significant improvement in pulmonary sarcoidosis measures.
  • Therapeutic doses have demonstrated efficacy in clinical trials.
  • The drug targets extracellular tRNA synthetase biology, indicating a novel mechanism.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is efzofitimod?

Efzofitimod is a therapeutic drug developed by Atyr Pharma targeting pulmonary sarcoidosis.

How does efzofitimod work?

It works by targeting extracellular tRNA synthetase biology, offering a novel treatment mechanism.

What were the results of the clinical trials?

The trials showed significant improvements in multiple efficacy measures for patients.

Who developed efzofitimod?

Efzofitimod is developed by Atyr Pharma, a biopharmaceutical company.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare efzofitimod pulmonary sarcoidosis Atyr Pharma clinical trials therapeutic doses
Last updated: Sep 10, 2023

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →